Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-07-18
2008-07-29
Marschel, Ardin H. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S456000, C546S141000, C549S287000
Reexamination Certificate
active
07405227
ABSTRACT:
Methods of treating ovarian cancer, endometrium cancer, cervical cancer, pancreatic cancer, bladder cancer, eve cancer, central nervous system cancer, thyroid cancer and lung cancer are disclosed. Specifically disclosed are methods of treating ovarian adenocarcinoma that has migrated into the abdominal cavity, a transitional cell carcinoma of the bladder, an epithelioid carcinoma in a pancreatic duct, an adenocarcinoma in a pancreatic duct, an adenocarcinoma in the cervical epithelium. The methods comprise administering to a patient a therapeutically effective amount of a compound of formula (Ia)wherein R1, R2, R3, R4, and R5are described herein, wherein at least two of the five R1, R2, R3, R4, and R5substituents are always hydrogen, at least one of the five substituents is always nitro, and at least one substituent positioned adjacent to a nitro is always iodo, and pharmaceutically acceptable salts thereof.
REFERENCES:
patent: 5232735 (1993-08-01), Kurtz et al.
patent: 5464871 (1995-11-01), Kun et al.
patent: 5482975 (1996-01-01), Kun et al.
patent: 5484951 (1996-01-01), Kun et al.
patent: 5516941 (1996-05-01), Kun et al.
patent: 5631038 (1997-05-01), Kurtz et al.
patent: 5631231 (1997-05-01), Kurtz et al.
patent: 5631232 (1997-05-01), Kurtz et al.
patent: 5631240 (1997-05-01), Kurtz et al.
patent: 5631252 (1997-05-01), Kurtz et al.
patent: 5631272 (1997-05-01), Kurtz et al.
patent: 5631292 (1997-05-01), Kurtz et al.
patent: 5631294 (1997-05-01), Kurtz et al.
patent: 5631295 (1997-05-01), Kurtz et al.
patent: 5631299 (1997-05-01), Kurtz et al.
patent: 5633282 (1997-05-01), Collins et al.
patent: 5637618 (1997-06-01), Kurtz et al.
patent: 5639788 (1997-06-01), Kurtz et al.
patent: 5641795 (1997-06-01), Kurtz et al.
patent: 5641799 (1997-06-01), Kurtz et al.
patent: 5641811 (1997-06-01), Kurtz et al.
patent: 5641812 (1997-06-01), Kurtz et al.
patent: 5643894 (1997-07-01), Kurtz et al.
patent: 5643941 (1997-07-01), Kurtz et al.
patent: 5643945 (1997-07-01), Kurtz et al.
patent: 5643955 (1997-07-01), Kurtz et al.
patent: 5643956 (1997-07-01), Kurtz et al.
patent: 5646122 (1997-07-01), Kurtz et al.
patent: 5650403 (1997-07-01), Kurtz et al.
patent: 5652367 (1997-07-01), Kun et al.
patent: 5654311 (1997-08-01), Kurtz et al.
patent: 5665755 (1997-09-01), Kurtz et al.
patent: 5670518 (1997-09-01), Kun et al.
patent: 5700792 (1997-12-01), Kurtz et al.
patent: 5703053 (1997-12-01), Kurtz et al.
patent: 5753674 (1998-05-01), Kun et al.
patent: 5837729 (1998-11-01), Bourinbaiar
patent: 5866608 (1999-02-01), Kurtz et al.
patent: 5874444 (1999-02-01), West
patent: 5877185 (1999-03-01), Kun et al.
patent: 5908861 (1999-06-01), Kun
patent: 6004978 (1999-12-01), Kun et al.
patent: 6008250 (1999-12-01), Kurtz et al.
patent: 6015792 (2000-01-01), Kurtz et al.
patent: 6303629 (2001-10-01), Kun
patent: 2005/0059824 (2005-03-01), Vaidyanathan et al.
patent: 2005/0113283 (2005-05-01), Solow-Cordero et al.
patent: 2007/0015837 (2007-01-01), Kun et al.
patent: 1768733 (2006-05-01), None
patent: 2456731 (1980-12-01), None
patent: 2000191612 (2000-07-01), None
patent: 2005336083 (2005-12-01), None
patent: 94/27584 (1994-12-01), None
patent: WO 94/27584 (1994-12-01), None
patent: WO 97/34593 (1997-09-01), None
patent: WO 01/04086 (2001-01-01), None
patent: WO 02/49992 (2002-06-01), None
patent: WO 03/007955 (2003-01-01), None
j. Med. Chem 1994 37, 2175.
Wolff, Manfred E. Burger's Medicinal Chemistry, fifth edition, John Wiley & Sons, 1995, pp. 975-977.
Banker, G.S. et al, “Modern Pharmaceutics, third edition.”, Marcel Dekker, New York, 1996, p. 596.
Erowld (2001) Introduction to the Federal Controlled Substance Analogue Act (pp. 1-4).
Green facts.org, 1 pge, Feb. 1, 2002.
Chen, et al. Potential for selective modulation of glutathione in cancer chemotherapy. Chem Biol Interact. 1998; 111-112:263-75.
Mendeleyev, et al. Potential chemotherapeutic activity of 4-iodo-3-nitrobenzamide. Metabolic reduction to the 3-nitroso derivative and induction of cell death in tumor cells in culture. Biochem Pharmacol. 1995; 50(5):705-14.
Rice, et al. Induction of Endonuclease-Mediated Apoptosis in Tumor Cells by C-Nitroso- Substituted Ligands of Poly(ADP-Ribose) Polymerase. Proceedings of the National Academy of Sciences. 1992; 89:7703-7707.
Astrazeneca International. Gefitinib (Iressa™) Lung Cancer ISEL Trial shows no overall survival advantage in a highly refractory population. Press release, Dec. 17, 2004. Available at: http://www.astrazeneca.com.pressrelease/4245.aspx Last accessed Mar. 4, 2008.
Bigler, et al. Evaluation of tamoxifen in persistent or recurrent nonsquamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. International Journal of Gynecological Cancer 2004;14(5):871-874.
Chustecka, Z. Adding Bevacizumab Not Beneficial in Pancreatic Cancer. 2007 Gastrointestinal Cancers Symposium. Presented Jan. 20, 2007.
Crowson, et al. A phase II study to evaluate tamoxifen in pancreatic adenocarcinoma. Eur J Surg Oncol. 1986;12(4):335-6.
Dongiovanni, et al. Gefitinib (ZD1839): Therapy in selected patients with non-small cell lung cancer (NSCLC)? Lung Cancer. Feb. 1, 2008 [Epub ahead of print] Availabel at: http://www.ncbi.nlm.gov/pubmed/18243402 Last accessed Mar. 5, 2008.
Duell, et al. A population-based study of the Arg399Gln polymorphism in X-ray repair cross-complementing group 1 (XRCC1) and risk of pancreatic adenocarcinoma. Cancer Res 2002;62:4630-6.
Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer. The Cochrane Database of Systematic Reviews 2008 Issue 1. Available at: http://www.cochrane.org/reviews/en/ab000486.html. Last accessed Mar. 4, 2008.
Edwards, et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature. 2008;451(7182):1111-5.
Fierce Biotech. Avastin encounters rare failure for pancreatic cancer. Fierce Biotech Web site. Jun. 26, 2006. Available at: http://www.fiercebiotech.com/story/avastin-encounters-rare-failure-for-pancreatic-cancer/2006-06-27 Last accessed Mar. 4, 2008.
Fisher, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994; 86:527-37.
Gurpide, E. Endometrial Cancer: Biochemical and Clinical Correlates. J Natl Cancer Inst 1991; 83(6): 405-416.
Hegi, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005 10;352(10):997-1003.
Ishii, et al. Efficacy of temozolomine is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas. Neurol Med Chir (Tokyo). Aug. 2007;47(8):341-9.
Kume, et al. Mutations in the serine protease inhibitor Kazal type 1 (Spink1) gene in Japanese patients with pancreatitis. Pancreatology 2005;5:354-60.
Kurman, R.J. Blaustein's Pathology of the Female Genital Tract. 4th ed. Springer-Verlag. New-York 1994.
Li, et al. Pancreatic cancer. Lancet 2004;363:1049-57.
Marchesi, et al. Triazene compounds: mechanism of action and related DNA repair systems. Pharmacol. Res. Oct. 2007; 56(4):275-87.
National Cancer Institute. Bevacizumab Combined With Chemotherapy Improves Progression-Free Survival for Patients With Advanced Breast Cancer. U.S. National Institutes of Health. 2005. Available at: http://www.cancer.gov
ewscenter/pressreleases/AvastinBreast. Last Accessed Mar. 4, 2008.
Paez, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004 4;304(5676):1497-500.
Pao, et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. Sep. 7, 2004;101(36):13306-11.
Porta, et al. Serum concentrations of organochlorine compounds and K-ras mutations in exocrine pancreatic cancer. PANKRAS II Study Group. Lancet 1999;354:2125-9.
Roche—Media News. US Phase III study of Avastin in advanced pancreatic cancer does not meet primary endpoint. Basel, Jun. 27, 2006. Roche Web site. Available at: http://www.roc
Basbaurn Carol
Kun Ernest
Lemjabbar-Alaoui Hassan
Mendeleyev Jerome
Ossovskaya Valeria
BiPAr Sciences, Inc.
Gembeh Shirley V
Grumbling Matthew V.
Halluin Albert P.
Marschel Ardin H.
LandOfFree
Treatment of cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3972673